The Relationship Between rs3212986C>A Polymorphism and Tumor Stage in Lung Cancer Patients

Abstract

Background The nucleotide excision repair (NER) system is one of the most important deoxyribonucleic acid (DNA) repair mechanisms and is critical for chemotherapy resistance. We conducted the present study to investigate the association between two polymorphisms of excision of repair cross-complementing group 1 (ERCC1), the key component of the NER pathway, and the clinicopathological features of patients with non-small cell lung cancer (NSCLC). Methods A total of 38 patients with confirmed NSCLC were included in our study. DNA was extracted from peripheral blood. ERCC1 rs3212986 (8092) and rs11615 (118) were genotyped using molecular assays including polymerase chain reaction (PCR) with restriction fragment length polymorphism (by MboII and HpyCH4 enzymes) and sequencing. Results The PCR results indicated the correct performance of the genomics extraction and molecular protocols. The distribution of C/C, C/A and A/A genotypes at position 8092 was 42.10%, 47.36%, and 10.52% respectively (P=0.03). Multivariate regression analysis showed that there was a significant correlation between C8092A (rs3212986) polymorphism and metastasis, grade of the tumor, and response to treatment. Individuals carrying the rs3212986 CA genotype and A allele had a significantly worse response to the treatment. Also, the correlation between alteration at this genomics location and patients with NSCLC who used to smoke cigarettes was positive. However, no significant association was detected between rs11615 C118>T polymorphism and demographic characteristics of patients with NSCLC. Conclusion We concluded that in lung cancer patients there is a relationship between tumor stage and rs3212986C>A polymorphism.

The association between the ERCC1/2 polymorphisms and radiotherapy efficacy in 87 patients with non-small cell lung cancer

“…Research on the ERCC1/2 gene polymorphisms in non-small cell lung cancer (NSCLC) has mainly focused on disease susceptibility and the efficacy and prognosis of platinum-based chemotherapy (3)(4)(5)(6)(7). Numerous studies have shown that the low expression of ERCC1 protein in tumor tissue can improve the sensitivity and survival of platinum-based chemotherapy patients.…”

Considering smoking status, coexpression network analysis of non–small cell lung cancer at different cancer stages, exhibits important genes and pathways

“…We then looked for those findings in other datasets including the GSE84339 from the GEO and also the TCGA data. We identified that in the GSE40419 data, the Red module contains CYP2A6, CYP4Z2P, FAM196B, FAM192A, KCNT1 and MLLT11 genes and the Turquoise module contains C7orf57, CAPSL, CCDC78, CD300LG, CYP2F1, DLEC1, DNAH6, FAM92B, LEFTY2, PI16, PPMIE, PZP, ROPN1L, RSPH1, SCGB1A1, SCGB3A1, SPAG6, TACR2 genes previously reported in association with the lung cancer.…”

The Association of ERCC1 and ERCC5 Polymorphisms with Lung Cancer Risk in Han Chinese

“…Other polymorphisms are also significantly associated with the risk of lung cancer; for example those in XRCC1 and TP53, especially in individuals aged over 50 years, whose detection allows the earlier diagnosis of disease [9]. ERCC1 and XRCC1 polymorphisms have also been significantly associated with the risk of lung cancer, especially in non-smokers [2][3][4][5]. Additionally, Chaszczewska et al reported that a nuclear factor kappa B subunit 2 polymorphism may be associated with NSCLC risk in the Polish population, and is a potential marker for NSCLC in men [10].…”

“…Lung cancer is one of the common malignant tumors in the world, and it remains the leading cause of cancer mortality because of its high malignant and metastatic potential [1]. Epidemiological studies of migrant populations point to a role for environmental and/or lifestyle factors in cancer etiology [2][3][4][5][6]. The occurrence of lung cancer is closely related to smoking, as shown by its observed downward trend in global incidence with the launch of anti-smoking campaigns; however, it still ranks first among all cancer types.…”